转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

Nature：慢性病毒感染免疫研究获突破

2016-08-15 Lilin Ye 《自然》

HIV乙肝肿瘤
关注

近日

近日，《自然》杂志在线发表由第三军医大学的研究成果，揭示了一群新的CD8+ T细胞亚类，阐明了其抑制病毒复制的机制。这一发现有助于理解慢性病毒感染免疫的关键环节，为根治HIV、乙肝等慢性病毒感染提供了新的可能。

此前研究发现，在慢性病毒感染过程中，病毒特异性的CD8+ T细胞显出医学界称为“功能耗竭”的现象。“但此时CD8+ T细胞并非不能识别病毒，数量也基本没减少，就像警察遇到一群歹徒，本该拔枪射击却无法启动杀伤武器。”该研究论著的通讯作者、第三军医大学教授叶丽林解释说。

但课题组通过研究发现，“功能耗竭”的CD8+ T细胞仍然具有一定的抗病毒功能，并在很大程度上控制病毒的复制。课题组称为CXCR5阳性CD8+ T细胞的亚类发挥着关键作用。在该项研究中，课题组还确定了Id2/E2A信号轴是生成这一细胞亚群的一个重要调控因子。

目前治疗HIV、乙肝、肿瘤等慢性病毒感染导致的疾病，化学药物只能在一定程度上抑制病毒复制，尚不能彻底根除。而叶丽林指出：“通过一定的手段，增加和稳定这一类CD8+ T细胞可以增强其清除病毒的功能。这为从根本上治愈这些疾病提供了新可能。”

下一步，他们将沿着这一新的研究策略，把研究成果运用到HIV和肿瘤的免疫治疗研究中。清华大学、复旦大学等机构的研究人员也参与了这项研究。

原始出处

Ran He, Shiyue Hou,Cheng Liu,Anli Zhang,Qiang Bai,Miao Han,Yu Yang,Gang Wei,Ting Shen, Xinxin Yang,Lifan Xu,Xiangyu Chen,Yaxing Hao,Pengcheng Wang,Chuhong Zhu, Juanjuan Ou,Houjie Liang,Ting Ni,Xiaoyan Zhang.et.al.Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection.nature.2016

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881260, encodeId=40be1881260d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Sep 25 06:09:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148574, encodeId=35fa1485e4ab, content=利国利民，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1271950233, createdName=优质青年, createdTime=Sat Oct 15 12:06:20 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263996, encodeId=cf051263996ab, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Wed Aug 17 01:09:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98997, encodeId=28ba9899e00, content=继续发扬，早日成功！, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Tue Aug 16 00:03:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98881, encodeId=30eb98881d5, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 18:46:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98880, encodeId=2356988806f, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 18:45:00 CST 2016, time=2016-08-15, status=1, ipAttribution=)]
    2016-09-25 仁心济世

    #Nat#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1881260, encodeId=40be1881260d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Sep 25 06:09:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148574, encodeId=35fa1485e4ab, content=利国利民，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1271950233, createdName=优质青年, createdTime=Sat Oct 15 12:06:20 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263996, encodeId=cf051263996ab, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Wed Aug 17 01:09:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98997, encodeId=28ba9899e00, content=继续发扬，早日成功！, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Tue Aug 16 00:03:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98881, encodeId=30eb98881d5, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 18:46:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98880, encodeId=2356988806f, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 18:45:00 CST 2016, time=2016-08-15, status=1, ipAttribution=)]
    2016-10-15 优质青年

    利国利民，加油！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1881260, encodeId=40be1881260d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Sep 25 06:09:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148574, encodeId=35fa1485e4ab, content=利国利民，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1271950233, createdName=优质青年, createdTime=Sat Oct 15 12:06:20 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263996, encodeId=cf051263996ab, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Wed Aug 17 01:09:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98997, encodeId=28ba9899e00, content=继续发扬，早日成功！, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Tue Aug 16 00:03:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98881, encodeId=30eb98881d5, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 18:46:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98880, encodeId=2356988806f, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 18:45:00 CST 2016, time=2016-08-15, status=1, ipAttribution=)]
    2016-08-17 qjddjq

    #慢性病#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1881260, encodeId=40be1881260d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Sep 25 06:09:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148574, encodeId=35fa1485e4ab, content=利国利民，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1271950233, createdName=优质青年, createdTime=Sat Oct 15 12:06:20 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263996, encodeId=cf051263996ab, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Wed Aug 17 01:09:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98997, encodeId=28ba9899e00, content=继续发扬，早日成功！, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Tue Aug 16 00:03:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98881, encodeId=30eb98881d5, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 18:46:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98880, encodeId=2356988806f, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 18:45:00 CST 2016, time=2016-08-15, status=1, ipAttribution=)]
    2016-08-16 明天会更好！

    继续发扬，早日成功！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1881260, encodeId=40be1881260d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Sep 25 06:09:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148574, encodeId=35fa1485e4ab, content=利国利民，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1271950233, createdName=优质青年, createdTime=Sat Oct 15 12:06:20 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263996, encodeId=cf051263996ab, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Wed Aug 17 01:09:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98997, encodeId=28ba9899e00, content=继续发扬，早日成功！, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Tue Aug 16 00:03:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98881, encodeId=30eb98881d5, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 18:46:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98880, encodeId=2356988806f, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 18:45:00 CST 2016, time=2016-08-15, status=1, ipAttribution=)]
    2016-08-15 忠诚向上

    好好学习一下

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1881260, encodeId=40be1881260d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Sep 25 06:09:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148574, encodeId=35fa1485e4ab, content=利国利民，加油！, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1271950233, createdName=优质青年, createdTime=Sat Oct 15 12:06:20 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263996, encodeId=cf051263996ab, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Wed Aug 17 01:09:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98997, encodeId=28ba9899e00, content=继续发扬，早日成功！, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Tue Aug 16 00:03:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98881, encodeId=30eb98881d5, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 18:46:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98880, encodeId=2356988806f, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 18:45:00 CST 2016, time=2016-08-15, status=1, ipAttribution=)]
    2016-08-15 忠诚向上

    好好学习一下

    0

相关资讯

Nature：从原子水平揭示为何HIV能够逃避免疫系统检测

来自英国医学研究委员会（MRC）分子生物学实验室和伦敦大学学院的研究人员发现HIV用来感染细胞同时逃避免疫系统检测的一种关键特征。这一发现提供一种新的药物靶标和重新评估现存HIV疗法以便改善它们的疗效的机会。相关研究结果于2016年8月10日在线发表在Nature期刊上，论文标题为“HIV-1 uses dynamic capsid pores to import nucleotides and

吉利德支持Genmab开发双特异性抗体治疗HIV

制药巨头吉利德公司最近宣布和丹麦生物技术公司Genmab达成了一项合作协议，利用后者开发的双特异性抗体技术平台开发治疗HIV的特效药物。按照协议，吉利德公司将获得Genmab公司专利技术的独家授权开发新型HIV疗法。此外，公司还有权开发另一种疾病的双特异性抗体药物。但两家公司均未透露第二种药物靶点信息。 作为回报，吉利德公司将向Genmab公司支付最高超过3亿美元的经费。这其中包括了

HIV关键性蛋白Nef研究取得重大进展

2016年8月10日/生物谷BIOON/--全世界有3600万多人感染上人类免疫缺陷病毒（HIV），其中美国有120万人感染上HIV。当前的抗逆转录病毒药物组合阻断HIV如何复制、成熟和入侵未被感染的细胞，但是这种组合不能够根除这种病毒。作为美国桑迪亚国家实验室（Sandia National Laboratories）生物与工程科学中心的一名研究员，Mike Kent正在研究参与HIV感染发

2016WHO指南——重点人群HIV感染的预防、诊断、治疗和护理发布

2016年7月，世界卫生组织(WHO)更新发布了重点人群HIV感染的预防，诊断，治疗和护理指南2016版。指南汇集了5类HIV感染的关键人群：男男同性性行为，毒品注射，监狱或其他封闭管理的人群，性工作者以及变性者。全文获取：下载地址：指南下载 (需要扣积分2分, 梅斯医学APP免积分下载)

Nat Immunol：科学家开发出治疗HIV等长效病毒感染的新疗法

图片来源：medicalxpress.com近日科学家们进行的一项最新研究距离发现治疗HIV感染及腺热病毒感染的新型疗法又近了一步，腺热病毒感染往往和淋巴瘤发生相关；某些感染，比如HIV感染并不能通过抗病毒疗法治疗，因为病毒可以进行有效地隐藏而不被机体免疫系统所差距。 来自莫纳什生物医学发现研究所及沃尔特与伊丽莎-霍尔研究所的研究人员通过研究发现，机体的杀伤性T细胞可以寻找到组织中隐藏的感染细胞

Lancet：前瞻性研究首次表明淋巴丝虫病可明显增加HIV的感染风险

在过去的十年里，关于蠕虫诱导的免疫激活是否会影响对HIV易感的个体一直存在争议。鉴于此，本研究评估了淋巴丝虫病对坦桑尼亚西南部HIV发病率的作用，淋巴丝虫病是一种由班氏丝虫引起的慢性寄生虫病。 在这项以人群为基础的队列研究中，研究人员按地理分层随机选择样本。2006年5月29日至2011年6月16日期间，研究人员共纳入了4283户家庭，涉及约18 000名参与者。所有的家庭成员进行随访和HI